IL308035A - Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists - Google Patents
Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonistsInfo
- Publication number
- IL308035A IL308035A IL308035A IL30803523A IL308035A IL 308035 A IL308035 A IL 308035A IL 308035 A IL308035 A IL 308035A IL 30803523 A IL30803523 A IL 30803523A IL 308035 A IL308035 A IL 308035A
- Authority
- IL
- Israel
- Prior art keywords
- pyrenyl
- triazole
- tetrahydro
- pyridine
- acetic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021091510 | 2021-04-30 | ||
| PCT/US2022/026832 WO2022232459A1 (en) | 2021-04-30 | 2022-04-28 | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308035A true IL308035A (en) | 2023-12-01 |
Family
ID=81748636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308035A IL308035A (en) | 2021-04-30 | 2022-04-28 | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250230140A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4330249A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024517769A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240044386A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117751106A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022264579A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218258A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308035A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012830A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022232459A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023109878A1 (zh) * | 2021-12-15 | 2023-06-22 | 武汉人福创新药物研发中心有限公司 | 三氮唑类lpar1拮抗剂及其用途 |
| CN121773091A (zh) * | 2023-09-08 | 2026-03-31 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
| IL326963A (en) * | 2023-09-08 | 2026-05-01 | Haisco Pharmaceutical Group Co Ltd | LPAR1 antagonist and its use |
| WO2026119206A1 (zh) * | 2024-12-05 | 2026-06-11 | 海思科医药集团股份有限公司 | Lpar1拮抗剂药物组合物及其在医药上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7369125B2 (ja) * | 2017-12-19 | 2023-10-25 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸 |
| CA3085561A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| KR20220024548A (ko) * | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 트리아졸 카르복실산 |
| IL300525A (en) * | 2020-08-11 | 2023-04-01 | Viva Star Biosciences Ltd | Triazole-pyridinyl-substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists |
-
2022
- 2022-04-28 CN CN202280040512.3A patent/CN117751106A/zh active Pending
- 2022-04-28 KR KR1020237041165A patent/KR20240044386A/ko active Pending
- 2022-04-28 EP EP22724318.5A patent/EP4330249A1/en active Pending
- 2022-04-28 CA CA3218258A patent/CA3218258A1/en active Pending
- 2022-04-28 US US18/557,918 patent/US20250230140A1/en active Pending
- 2022-04-28 WO PCT/US2022/026832 patent/WO2022232459A1/en not_active Ceased
- 2022-04-28 JP JP2023566850A patent/JP2024517769A/ja active Pending
- 2022-04-28 MX MX2023012830A patent/MX2023012830A/es unknown
- 2022-04-28 IL IL308035A patent/IL308035A/en unknown
- 2022-04-28 AU AU2022264579A patent/AU2022264579A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012830A (es) | 2024-01-19 |
| WO2022232459A1 (en) | 2022-11-03 |
| US20250230140A1 (en) | 2025-07-17 |
| EP4330249A1 (en) | 2024-03-06 |
| CN117751106A (zh) | 2024-03-22 |
| AU2022264579A1 (en) | 2023-12-14 |
| CA3218258A1 (en) | 2022-11-03 |
| JP2024517769A (ja) | 2024-04-23 |
| KR20240044386A (ko) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4582426A4 (en) | PAN-KRAS INHIBITOR COMPOUND | |
| EP4610263A4 (en) | PAN-KRAS INHIBITOR COMPOUND | |
| EP4138818C0 (en) | Injectable formulation | |
| IL288174A (en) | Pyrrolidine compounds | |
| EP4351568A4 (en) | HALLUCINOGEN-FATTY ACID COMBINATION | |
| EP4227390A4 (en) | COMPOSITION CONTAINING A REFRIGERANT FLUID | |
| EP4148096A4 (en) | COMPOSITION | |
| EP4094582A4 (en) | COMPOSITION | |
| EP4061813C0 (en) | PYRROLIDINE DERIVATIVES | |
| DK4055021T3 (da) | Heterocykliske rip1-inhiberende forbindelser | |
| DK4259617T3 (da) | Substituerede pyrazolpiperidincarboxylsyrer | |
| EP4161580A4 (en) | BIOCONJUGATES OF CANNABINOID HYALURONIC ACID | |
| EP4279545A4 (en) | COMPOSITION | |
| EP4304549A4 (en) | Antibiofilm preservative compositions | |
| EP4213818C0 (en) | OPTIMIZED INJECTABLE VETERINARY FORMULATION | |
| EP4291042C0 (en) | COMPOSITION DERIVED FROM OATS | |
| EP4744631A1 (en) | Cannula | |
| EP4656252A4 (en) | COMPOSITION | |
| EP4553110A4 (en) | COMPOSITION | |
| JP1762087S (ja) | フィールドスコープ | |
| EP4509561A4 (en) | COMPOSITION | |
| EP4473837A4 (en) | COMPOSITION | |
| EP4460553C0 (en) | ANTIFUNGAL COMPOSITION | |
| EP4132523A4 (en) | Novel n-aryl oxamic acids | |
| EP4223850A4 (en) | COMPOSITION |